Metabolic Effects and Safety Profile of Nebivolol
- 1 December 2001
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 38, S33-S35
- https://doi.org/10.1097/00005344-200112003-00006
Abstract
Summary: Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) release. This dual mechanism of action leads to effective control of blood pressure at a low degree of β-blockade and explains the lack of any interference with lipid metabolism. For the same reason, the tolerability profile of nebivolol is highly favorable compared with the classical β-blockers, with less fatigue and dyspnea in hypertensive subjects, and with an improvement of functional capacity and exercise tolerance in patients with left ventricular dysfunction. Furthermore, contrary to atenolol and propranolol, nebivolol does not diminish specific airway conductance. Compared with other first-line antihypertensive agents, nebivolol was shown to be better tolerated than nifedipine and enalapril, and to have a positive effect on general wellbeing. Among the currently available antihypertensive drugs, nebivolol therefore appears to have a most alteractive safety and tolerability profile, which can be attributed to its NO-mediated effects allowing effective control of hypertension at a lower degree of β-blockade than with first-generation γ-blockers.Keywords
This publication has 15 references indexed in Scilit:
- ControversyPublished by Oxford University Press (OUP) ,1999
- Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetesJournal of Human Hypertension, 1997
- Nitric oxide mediated venodilator effects of nebivolol.British Journal of Clinical Pharmacology, 1994
- Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma LipoproteinsThe Journal of Clinical Pharmacology, 1992
- Exercise tolerance with nebivolol and atenololCardiovascular Drugs and Therapy, 1992
- Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular DiseaseDiabetes Care, 1991
- The Receptor Binding Profile of the New Antihypertensive Agent Nebivolol and its Stereoisomers Compared with Various β-Adrenergic BlockersClinical Drug Investigation, 1991
- Optimizing cardiovascular risk reduction during antihypertensive therapy.Hypertension, 1990
- Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.BMJ, 1989
- Antihypertensive Treatment and Serum LipoproteinsJournal Of Hypertension, 1985